The Unmet Need:

Each year in the U.S., over 600,000 people die due to cancer.  The majority of these deaths are due to the unresolved problem of drug resistance. 
Most fatal cancers are drug resistant.

Technology

BRG drugs are a new family of therapeutic agents that, based on our preclinical study results, induce broad anticancer and antiviral effects.
They deliver two ingredients:
(1) 2, -3(aminopropyl)amino ethane thiol (NCI nomenclature - APAET)
(2) a thiol-PEG polymer that can be varied for each BRG drug
The first active ingredient (APAET) is the active form of BRG drugs and also of an older FDA-approved drug that has reported, in the peer-reviewed literature, cell protective effects in normal cells and anticancer and antiviral effects is diseased cells.

Our Solution:

Based on our laboratory data, BRG drugs work in human cancer types that have few to no effective treatments, and they alter tumor cell resistance to selected anticancer agents so that all to nearly all tumor cells are killed after just one exposure to the two anticancer agents together.

BRG drugs are different - SAFETY

Based on our preclinical studies:

Drug safety is critical for the use of any therapeutic agent.
Cisplatin is a commonly used anticancer agent, but its use is limited by its toxicity.  It suppressed the growth &/or kills 50% of tumors cells at a dose that is ~7 microM.
BRG drugs deliver two ingredients.
(1)The major one is FDA-approved as the active form of an older, cell protective agent.
(2)The other ingredient is a common drug conjugate used in FDA-approved drugs.
BRG-4 did not achieve IC50 level effects (it did not suppress the growth or kill) 50% of normal (primary) cells at the highest doses that could be dissolved.

BRG drugs are different - ANTICANCER EFFECTS

Based on our preclinical studies:

We compared the effectiveness of cisplatin in human cancer cell lines representative of lung cancers, malignant pleural mesotheliomas, and ovarian cancers.
Cisplatin did no kill 50% of the tumor cells in any of these human cancer cell lines even at doses greater than 25 microM – these results are indicated by the dotted open boxes with astericks.
BRG-4 killed 50% of the cancer cells in all cell lines at doses that are well below the doses that stop normal cells from growing.

In progress - please check back later